| scholarly article | Q13442814 |
| P50 | author | Joshua S Rodefer | Q60315778 |
| P2093 | author name string | Jørn Arnt | |
| Jens-Jakob Karlsson | |||
| Tuyet N Nguyen | |||
| P2860 | cites work | 5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex | Q28184669 |
| The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus | Q28202463 | ||
| 5-ht6 receptors | Q28245286 | ||
| Dissociation in prefrontal cortex of affective and attentional shifts | Q28275885 | ||
| Recent advances in the phencyclidine model of schizophrenia | Q29618917 | ||
| The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia | Q33537860 | ||
| The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia | Q33693516 | ||
| Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? | Q33886050 | ||
| 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. | Q34138219 | ||
| SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. | Q34577251 | ||
| 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus | Q34598742 | ||
| Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic | Q36179715 | ||
| 5-HT6 receptors: a novel target for cognitive enhancement | Q36187762 | ||
| Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis | Q36510741 | ||
| Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia | Q38037996 | ||
| Cognitive function in schizophrenia--do neuroleptics make a difference? | Q40899271 | ||
| What are the functional consequences of neurocognitive deficits in schizophrenia? | Q40976267 | ||
| Do neuroleptics impair learning in schizophrenic patients? | Q41175914 | ||
| Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses | Q41348477 | ||
| Cognitive function in schizophrenia | Q41628160 | ||
| Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence | Q41682564 | ||
| Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. | Q42165175 | ||
| Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder | Q44013096 | ||
| 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner | Q44100868 | ||
| Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs | Q44317351 | ||
| R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram | Q44748370 | ||
| Do clozapine and risperidone affect social competence and problem solving? | Q44750298 | ||
| Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting | Q45014687 | ||
| Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia | Q45245234 | ||
| PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats | Q46401337 | ||
| 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats | Q46450693 | ||
| The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study | Q46702970 | ||
| Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial | Q46732032 | ||
| A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia | Q46827385 | ||
| Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models | Q46829192 | ||
| Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. | Q46887843 | ||
| The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm | Q46962812 | ||
| Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? | Q46972062 | ||
| Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. | Q47353682 | ||
| Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage | Q48165305 | ||
| Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. | Q48257888 | ||
| The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors | Q48278659 | ||
| The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia | Q48361872 | ||
| Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia | Q48398191 | ||
| Perceptual attentional set-shifting is impaired in rats with neurotoxic lesions of posterior parietal cortex. | Q48407039 | ||
| Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. | Q50674832 | ||
| Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | Q50679599 | ||
| Neurocognitive and social functioning in schizophrenia. | Q51986093 | ||
| Naltrexone reverses age-induced cognitive deficits in rats. | Q52002146 | ||
| Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. | Q52013790 | ||
| The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. | Q52046325 | ||
| Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. | Q52048859 | ||
| Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. | Q52051962 | ||
| Medial frontal cortex mediates perceptual attentional set shifting in the rat. | Q52168274 | ||
| Neuroleptic drug effects on cognitive function in schizophrenia | Q68166120 | ||
| In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics | Q73263546 | ||
| Convergence of cognitive and adaptive decline in late-life schizophrenia | Q78168649 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attention | Q6501338 |
| P304 | page(s) | 2657-2666 | |
| P577 | publication date | 2007-12-19 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics | |
| P478 | volume | 33 |
| Q47307672 | A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. |
| Q37585410 | ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility. |
| Q35041190 | Alzheimer's disease and age-related memory decline (preclinical) |
| Q43181191 | Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit |
| Q33605869 | Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia |
| Q46859633 | Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism |
| Q46313880 | Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions |
| Q38731646 | Attentional Set-Shifting Across Species |
| Q48079038 | Attentional Set-Shifting Paradigm in the Rat. |
| Q92626334 | Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review |
| Q37081349 | Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration |
| Q38026886 | Clozapine for the treatment of schizophrenia |
| Q30444469 | Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats |
| Q50576901 | Comparing the effects of subchronic phencyclidine and medial prefrontal cortex dysfunction on cognitive tests relevant to schizophrenia. |
| Q46661372 | Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study |
| Q35040839 | Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching |
| Q33976994 | Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia |
| Q43152159 | Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. |
| Q48691924 | Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study. |
| Q42961384 | Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole |
| Q34680922 | Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis |
| Q34300628 | Drug safety and efficacy evaluation of sertindole for schizophrenia |
| Q45977455 | Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. |
| Q37112450 | Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice |
| Q46927168 | Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex |
| Q35748684 | Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats |
| Q42427678 | Emerging role of sertindole in the management of schizophrenia |
| Q34129334 | Emerging treatments in the management of schizophrenia - focus on sertindole |
| Q38482078 | Executive function. |
| Q50684220 | In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia. |
| Q37354597 | Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment |
| Q34480719 | Ketamine and phencyclidine: the good, the bad and the unexpected |
| Q48482293 | Lesions of the orbital prefrontal cortex impair the formation of attentional set in rats. |
| Q34034134 | Modeling deficits in attention, inhibition, and flexibility in HAND. |
| Q34236634 | Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats |
| Q48767121 | PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. |
| Q34661221 | Pharmacological enhancement of memory and executive functioning in laboratory animals. |
| Q34125605 | Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia |
| Q39424256 | Prefrontal cortex executive processes affected by stress in health and disease |
| Q46038344 | Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. |
| Q41569283 | Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials |
| Q37809874 | Sertindole for the treatment of schizophrenia. |
| Q35009210 | Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms |
| Q38236032 | Sertindole in schizophrenia: efficacy and safety issues. |
| Q82301757 | Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP |
| Q44655683 | The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats. |
| Q42703159 | The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice |
| Q36797180 | The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats |
| Q38526546 | The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia |
| Q34689461 | Translational Aspects of the Novel Object Recognition Task in Rats Abstinent Following Sub-Chronic Treatment with Phencyclidine (PCP): Effects of Modafinil and Relevance to Cognitive Deficits in Schizophrenia |
| Q55216457 | Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. |
| Q46099857 | Ventral striatal dopamine modulation of different forms of behavioral flexibility |
| Q52645959 | Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. |
Search more.